Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > April 3, 2020
Daily News
April 3, 2020
- MHLW Allows Online IRB Meetings for Coronavirus Trials
April 3, 2020
- Denka to Resume Production of Compound for Avigan
April 3, 2020
- Japan’s Stimulus Package Likely to Support API Manufacturing Repatriation, Vaccine/Drug Development
April 3, 2020
- Companies “May” Provide Information to Individual Patients at Their Request: MHLW
April 3, 2020
- Alfresa Allies with Cell Therapy Startup; Possible Tripartite Collaboration with Rohto
April 3, 2020
- Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister
April 3, 2020
- Takeda Launches Dedicated COVID-19 Website to Inform of Product Supply, R&D Status
April 3, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…